Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?

Leukemia

Volumn 19, Issue 8, 2005, Pages 1324-1327

  Rowe, Jimmy M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; APOPTOSIS INHIBITOR; CYCLOSPORIN A; CYTARABINE; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; OBLIMERSEN; PLACEBO; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; DRUG MEGADOSE; DRUG TOLERABILITY; FOLLOW UP; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INCIDENCE; LOW DRUG DOSE; MAINTENANCE THERAPY; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

EID: 23844507573     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403827     Document Type: Article

References (23)

1. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G et al. Low-dose cytarabine vs intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 8: 272-279.
2. Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268-1274.
3. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ et al. A phase III study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479-485.
4. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
5. Estey E. Clinical trials in AML of the elderly: should we change our methodology? Leukemia 2004; 18: 1772-1774.
6. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia 2000; 14: 480-487.
7. Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699-1704.
8. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE, Medical Research Council Adult Leukemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302-1311.
9. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C, et al., German AML Cooperative Group. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21: 4496-4504.
10. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98: 548-553.
11. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457-462.
12. Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T et al. G3139, a BCL-2 antisense oligo-nucleotide, in AML. Ann Hematol 2004; 83 (Suppl 1): S93-S94.
13. Lehne G, De Angelis P, den Boer M, Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 1999; 13: 768-778.
14. Mauritzson N, Johansson B, Albin M, Rylander L, Billstrom R, Ahlgren T et al. Survival time in a population-based consecutive series of adult acute myeloid leukemia - the prognostic impact of karyotype during the time period 1976-1993. Leukemia 2000; 14: 1039-1043.
15. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al., Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
16. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005; 19: 176-182.
17. Liesveld JL, Lancet JE, Rosell KE, Menon A, Lu C, McNair C et al. Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia 2003; 17: 1806-1812.
18. Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002; 16: 2027-2036.
19. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004; 18: 1246-1251.
20. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, MAPkinase and p53 pathways. Leukemia 2005; 19: 586-594.
21. Turzanski J, Grundy M, Russell NH, Pallis M. Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia 2004; 18: 1662-1670.
22. Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, et al., AML Study Group Ulm. Phase III study of all- trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004; 18: 1798-1803.
23. Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100: 3869-3876.